POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.433
https://www.valueinhealthjournal.com/article/S1098-3015(21)02228-2/fulltext
Title :
POSB160 Cost-Effectiveness of Dapagliflozin Compared to DPP-4 Inhibitors as Combination Therapy with Metformin in the Treatment of Type 2 Diabetes Mellitus without Established Cardiovascular Disease in Colombia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02228-2&doi=10.1016/j.jval.2021.11.433
First page :
Section Title :
Open access? :
No
Section Order :
11210